on July 31, 2003
Published online before print July 31, 2003, doi: 10.1161/01.ATV.0000089330.88461.D6
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 20, 2003
Accepted on July 2, 2003
Mechanisms Involved in Adenosine Triphosphate-Induced Platelet Aggregation in Whole Blood
Nicholas P. Stafford ;
From the Centre for Integrated Systems Biology and Medicine, University of Nottingham, UK.
* To whom correspondence should be addressed. E-mail: s.heptinstall{at}nottingham.ac.uk.
Objective--Effects on platelet aggregation of adenosine triphosphate (ATP) released from damaged cells and from platelets undergoing exocytosis have not been clearly established. In this study we report on the effects of ATP on platelet aggregation in whole blood.
Methods and Results--Aggregation, measured using a platelet-counting technique, occurred in response to ATP and was maximal at 10 to 100 µmol/L. It was abolished by MRS2179, AR-C69931, and creatine phosphate/creatine phosphokinase, implying that conversion to adenosine diphosphate (ADP) is required. ATP did not induce aggregation in platelet-rich plasma, but aggregation did occur when apyrase or hexokinase was added. Aggregation also occurred after addition of leukocytes to platelet-rich plasma (as a source of ecto-ATPase), and this was potentiated on removal of adenosine by adenosine deaminase, indicating that adenosine production modulates the response. Dipyridamole, which inhibits adenosine uptake into erythrocytes, inhibited aggregation induced by ATP in whole blood, and adenosine deaminase reversed this. DN9693 and forskolin synergized with dipyridamole to inhibit ATP-induced aggregation.
Conclusions--ATP induces aggregation in whole blood via conversion of ATP to ADP by ecto-ATPases on leukocytes. This is inhibited by agents that prevent adenosine removal. Reduced aggregation at high concentrations of ATP (>100 µmol/L) may be a consequence of inhibition by ATP of ADP action at ADP receptors.
Key words: ATP • ADP • platelet aggregation • leukocytes • ecto-ATPase
This article has been cited by other articles:
 |
|
 |
|
  M. Zebisch and N. Strater Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling PNAS, May 13, 2008; 105(19): 6882 - 6887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li Platelet-lymphocyte cross-talk J. Leukoc. Biol., May 1, 2008; 83(5): 1069 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Becker Emerging constructs to maintain safety among patients with acute coronary syndromes requiring surgical coronary revascularization Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D12 - D22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Michno, H. Bielarczyk, T. Pawelczyk, A. Jankowska-Kulawy, J. Klimaszewska, and A. Szutowicz Alterations of Adenine Nucleotide Metabolism and Function of Blood Platelets in Patients With Diabetes Diabetes, February 1, 2007; 56(2): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heptinstall, J. R. Glenn, A. Johnson, B. Myers, A. E. White, and L. Zhao Leukocytosis, Vascular Disease, and Adenine Nucleotide Metabolism Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): e22 - e23. [Full Text] [PDF]
|
|
|
|
 |
|
 U. S. Tantry, K. P. Bliden, and P. A. Gurbel Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1705 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Freedman Molecular Regulation of Platelet-Dependent Thrombosis Circulation, October 25, 2005; 112(17): 2725 - 2734. [Abstract] [Full Text] [PDF]
|
|